CRISPR systems are derived from bacterial adaptive immunity and have been repurposed as molecular scissors to change DNA sequences in human cells. The core components are a nuclease protein such as Cas9 and an RNA molecule that directs the nuclease to a specific DNA sequence. Recognition of the target requires both sequence complementarity between the RNA guide and the DNA and a short adjacent motif called the protospacer adjacent motif or PAM. For Streptococcus pyogenes Cas9 the PAM sequence is NGG, which constrains where edits can occur in the genome.
Molecular mechanism
A single-guide RNA combines elements of two natural RNAs into one molecule that binds Cas9 and base-pairs with the target DNA. Jennifer Doudna at University of California, Berkeley and Emmanuelle Charpentier at Umeå University showed that a programmable RNA–guided Cas9 complex can cleave double-stranded DNA, establishing the basic editing principle. When Cas9 binds a correctly matched site and a compatible PAM, it generates a double-strand break. That break is the entry point for cellular repair machinery to change the sequence.
The exact edit produced depends on how the cell repairs the break. Non-homologous end joining often rejoins ends imperfectly, producing small insertions or deletions that can disrupt a gene. Homology-directed repair uses a supplied DNA template to replace or correct sequences, enabling precise changes if the template is present. Feng Zhang at Broad Institute and Massachusetts Institute of Technology adapted Cas9 for efficient use in mammalian cells and reported editing in human cells, demonstrating that these repair pathways can be harnessed to produce both knockouts and precise corrections.
Delivery, specificity, and biological outcomes
Getting the CRISPR machinery into human tissues is a major technical and clinical challenge. Delivery approaches include viral vectors such as adeno-associated virus, lipid nanoparticles, and ex vivo editing of extracted stem cells that are returned to the patient. Each method has trade-offs in efficiency, immune response, and tissue reach. Off-target cleavage at similar genomic sequences remains a safety concern; engineering of high-fidelity Cas variants and careful guide design reduce but do not eliminate that risk. Cells can also respond with immune reactions to bacterial proteins, and mosaicism can occur if edits happen after the first cell divisions in embryos, making outcomes unpredictable.
Clinical and societal consequences extend beyond individual patients. CRISPR-based therapies show promise for genetic blood disorders and some cancers, but unequal access, regulatory divergence, and cultural attitudes toward germline alteration influence who benefits. The case of He Jiankui at Southern University of Science and Technology, who reported germline editing of embryos, illustrates how technical capability can collide with ethical norms and legal frameworks, prompting global calls for oversight from bodies such as the World Health Organization. Environmental applications like gene drives raise territorial and ecosystem concerns because edited organisms can spread beyond borders, affecting biodiversity and local livelihoods.
Understanding how CRISPR edits human genes therefore requires attention to molecular mechanisms, delivery and repair biology, and the social, regulatory, and environmental contexts that determine whether and how edits are deployed. Scientific progress reduces technical barriers, but risk management and inclusive governance shape real-world consequences.